| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets and Chemical Biology |
1 Fox Chase Cancer Center, Philadelphia, Pennsylvania; 2 University of California at San Francisco, San Francisco, California; and 3 G.E. Global Research, Niskayuna, New York
Requests for reprints: Gregory P. Adams, Fox Chase Cancer Center, Department of Medical Oncology, Medical Science Division, 333 Cottman Avenue, W364, Philadelphia, PA 19111. Phone: 215-728-3890; 215-728-2741; E-mail: gp_adams{at}fccc.edu.
Positron emission tomography (PET) provides an effective means of both diagnosing/staging several types of cancer and evaluating efficacy of treatment. To date, the only U.S. Food and Drug Administration–approved radiotracer for oncologic PET is 18F-fluoro-deoxyglucose, which measures glucose accumulation as a surrogate for malignant activity. Engineered antibody fragments have been developed with the appropriate targeting specificity and systemic elimination properties predicted to allow for effective imaging of cancer based on expression of tumor associated antigens. We evaluated a small engineered antibody fragment specific for the HER2 receptor tyrosine kinase (C6.5 diabody) for its ability to function as a PET radiotracer when labeled with iodine-124. Our studies revealed HER2-dependent imaging of mouse tumor xenografts with a time-dependent increase in tumor-to-background signal over the course of the experiments. Radioiodination via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter without affecting the ability to image the tumor xenografts. In addition, we validated a method for using a clinical PET/computed tomography scanner to quantify tumor uptake in small-animal model systems; quantitation of the tumor targeting by PET correlated with traditional necropsy-based analysis at all time points analyzed. Thus, diabodies may represent an effective molecular structure for development of novel PET radiotracers.
Key Words: HER2 • Antibody • PET • Imaging
This article has been cited by other articles:
|
|
 |
|
  G. Kramer-Marek, D. O. Kiesewetter, and J. Capala Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules J. Nucl. Med., July 1, 2009; 50(7): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Leyton, T. Olafsen, M. A. Sherman, K. B. Bauer, P. Aghajanian, R. E. Reiter, and A. M. Wu Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Protein Eng. Des. Sel., March 1, 2009; 22(3): 209 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orlova, H. Wallberg, S. Stone-Elander, and V. Tolmachev On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model J. Nucl. Med., March 1, 2009; 50(3): 417 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wu Antibodies and Antimatter: The Resurgence of Immuno-PET J. Nucl. Med., January 1, 2009; 50(1): 2 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asano, Y. Sone, K. Ikoma, H. Hayashi, T. Nakanishi, M. Umetsu, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528 Protein Eng. Des. Sel., October 1, 2008; 21(10): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Gee, R. Upadhyay, H. Bergquist, H. Alencar, F. Reynolds, M. Maricevich, R. Weissleder, L. Josephson, and U. Mahmood Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/neu-targeted Therapy Radiology, September 1, 2008; 248(3): 925 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Kim, C. F. McDonagh, L. Westendorf, L. L. Brown, D. Sussman, T. Feist, R. Lyon, S. C. Alley, N. M. Okeley, X. Zhang, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity Mol. Cancer Ther., August 1, 2008; 7(8): 2486 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Lee, M. Hassan, R. Fisher, O. Chertov, V. Chernomordik, G. Kramer-Marek, A. Gandjbakhche, and J. Capala Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging Clin. Cancer Res., June 15, 2008; 14(12): 3840 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications Oncologist, December 1, 2007; 12(12): 1379 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lofblom, J. Sandberg, H. Wernerus, and S. Stahl Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications Appl. Envir. Microbiol., November 1, 2007; 73(21): 6714 - 6721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Cancer Res., March 1, 2007; 67(5): 2178 - 2186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lubberink, A. van Schie, H. W.A.M. de Jong, G. A.M.S. van Dongen, and G. J.J. Teule Acquisition Settings for PET of 124I Administered Simultaneously with Therapeutic Amounts of 131I J. Nucl. Med., August 1, 2006; 47(8): 1375 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
